Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression

Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression

Clinically silent corticotroph tumors are usually macroadenomas that comprise 20% of ACTH tumors. They frequently progress to aggressive tumors with high recurrence, invasiveness, and on rare occasions, they may become hormonally active causing Cushing’s disease. Trustable biomarkers that can predic...

Full description

Bibliographic Details
Main Authors: Gianina Demarchi, Sofía Perrone, Gaela Esper Romero, Cristian De Bonis, Juan Pablo Casasco, Gustavo Sevlever, Silvia Ines Berner, Carolina Cristina
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Endocrinology
Subjects:
ACTH
tumor transformation
β-Catenin
temozolomide
corticotroph tumor
vasculature
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.870172/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.870172/full

Similar Items